JPWO2020227483A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020227483A5 JPWO2020227483A5 JP2021566150A JP2021566150A JPWO2020227483A5 JP WO2020227483 A5 JPWO2020227483 A5 JP WO2020227483A5 JP 2021566150 A JP2021566150 A JP 2021566150A JP 2021566150 A JP2021566150 A JP 2021566150A JP WO2020227483 A5 JPWO2020227483 A5 JP WO2020227483A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- item
- domain
- cell
- intracellular signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025031484A JP2025078698A (ja) | 2019-05-08 | 2025-02-28 | 操作されたｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845311P | 2019-05-08 | 2019-05-08 | |
| US62/845,311 | 2019-05-08 | ||
| PCT/US2020/031796 WO2020227483A1 (en) | 2019-05-08 | 2020-05-07 | Engineered t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025031484A Division JP2025078698A (ja) | 2019-05-08 | 2025-02-28 | 操作されたｔ細胞 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022532557A JP2022532557A (ja) | 2022-07-15 |
| JP2022532557A5 JP2022532557A5 (https=) | 2023-05-15 |
| JPWO2020227483A5 true JPWO2020227483A5 (https=) | 2023-05-15 |
| JP7723887B2 JP7723887B2 (ja) | 2025-08-15 |
Family
ID=73051184
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566150A Active JP7723887B2 (ja) | 2019-05-08 | 2020-05-07 | 操作されたｔ細胞 |
| JP2025031484A Pending JP2025078698A (ja) | 2019-05-08 | 2025-02-28 | 操作されたｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025031484A Pending JP2025078698A (ja) | 2019-05-08 | 2025-02-28 | 操作されたｔ細胞 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12590136B2 (https=) |
| EP (1) | EP3966235A4 (https=) |
| JP (2) | JP7723887B2 (https=) |
| KR (1) | KR20220030933A (https=) |
| CN (2) | CN120939220A (https=) |
| AU (1) | AU2020267641B2 (https=) |
| BR (1) | BR112021022303A2 (https=) |
| CA (1) | CA3139011A1 (https=) |
| CL (1) | CL2021002935A1 (https=) |
| CO (1) | CO2021016480A2 (https=) |
| EA (1) | EA202193074A1 (https=) |
| IL (1) | IL287777A (https=) |
| MA (1) | MA55911A (https=) |
| MX (1) | MX2021013588A (https=) |
| SG (1) | SG11202111973RA (https=) |
| WO (1) | WO2020227483A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| IL266628B2 (en) | 2016-11-17 | 2024-06-01 | Bluebird Bio Inc | TGFBeta signal converter |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| KR20220030933A (ko) | 2019-05-08 | 2022-03-11 | 메디진 이뮤노테라피스 게엠바하 | 조작된 t 세포 |
| AU2021244594A1 (en) * | 2020-03-27 | 2022-12-01 | Regeneron Pharmaceuticals, Inc. | T cell receptors |
| JP2024514556A (ja) * | 2021-04-15 | 2024-04-02 | レジェンド バイオテック ユーエスエイ インコーポレイテッド | 融合タンパク質及びその使用法 |
| TW202317602A (zh) * | 2021-07-15 | 2023-05-01 | 福瑞德哈金森腫瘤中心 | 嵌合多肽 |
| IL312182A (en) * | 2021-10-20 | 2024-06-01 | Fate Therapeutics Inc | Effector cells and their use for autologous cell-based therapy against tumors |
| GB202115329D0 (en) * | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| EP4479068A4 (en) * | 2022-02-18 | 2026-01-07 | Univ California | ENHANCED MULTIPLICATION AND FUNCTION OF PRIMARY HUMAN NK CELLS BY A CHIMERICAL CYTOKINE RECEPTOR |
| USD1083734S1 (en) * | 2022-08-01 | 2025-07-15 | Hyundai Motor Company | Wheel for automobile |
| JP2026503660A (ja) * | 2023-01-27 | 2026-01-29 | ジェンティバイオ インコーポレイテッド | 操作された修復調節性ｔ細胞 |
| WO2025047925A1 (ja) * | 2023-08-31 | 2025-03-06 | 国立大学法人三重大学 | ハイブリッドｔ細胞受容体 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US7157091B1 (en) | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| AU2002321581C1 (en) | 2001-08-31 | 2008-09-18 | Adaptimmune Limited | Soluble T cell receptor |
| US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
| EP1783228A1 (en) | 2005-11-08 | 2007-05-09 | ETH Zürich | Recombinant expression of multiprotein complexes using polygenes |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| WO2011024791A1 (ja) | 2009-08-25 | 2011-03-03 | タカラバイオ株式会社 | レチノイン酸存在下でのｔ細胞集団の製造方法 |
| SG10201505217WA (en) | 2010-07-09 | 2015-08-28 | Biogen Hemophilia Inc | Chimeric clotting factors |
| CN107164330A (zh) | 2011-04-08 | 2017-09-15 | 贝勒医学院 | 使用嵌合细胞因子受体逆转肿瘤微环境的影响 |
| DK2806883T3 (da) | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| IL286786B (en) | 2012-09-14 | 2022-09-01 | The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst | T cell receptors that recognize mhc mage–a3 are restricted type ii |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| CA2909701C (en) | 2013-04-17 | 2022-12-06 | Baylor College Of Medicine | Immunosuppressive tgf-.beta. signal converter |
| WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| EP2944652A1 (en) | 2014-05-13 | 2015-11-18 | Technische Universität München | Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| US10828353B2 (en) | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| US10227392B2 (en) | 2015-04-06 | 2019-03-12 | Acceleron Pharma Inc. | ALK7:ActRIIB heteromultimers and uses thereof |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| CA2938473A1 (en) | 2015-08-04 | 2017-02-04 | Fiberbuilt Manufacturing Inc. | Golf practice device |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| SMT202100564T1 (it) | 2016-04-08 | 2022-01-10 | Adaptimmune Ltd | Recettori di cellule t |
| PL3440105T3 (pl) | 2016-04-08 | 2022-08-29 | Immunocore Limited | Receptory komórek t |
| RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| JP6699423B2 (ja) | 2016-07-21 | 2020-05-27 | コニカミノルタ株式会社 | 定着装置および画像形成装置 |
| CN110139873A (zh) | 2016-10-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| IL266628B2 (en) | 2016-11-17 | 2024-06-01 | Bluebird Bio Inc | TGFBeta signal converter |
| US11497768B2 (en) | 2017-06-05 | 2022-11-15 | Mie University | Antigen-binding protein that recognizes MAGE-A4-derived peptide |
| AU2018318303A1 (en) | 2017-08-18 | 2020-04-09 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| EP3695408B1 (en) | 2017-10-02 | 2026-01-21 | The Broad Institute, Inc. | Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer |
| WO2019238023A1 (en) | 2018-06-11 | 2019-12-19 | Chineo Medical Technology Co., Ltd. | Neoantigen vaccines and uses thereof |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| KR20220030933A (ko) | 2019-05-08 | 2022-03-11 | 메디진 이뮤노테라피스 게엠바하 | 조작된 t 세포 |
-
2020
- 2020-05-07 KR KR1020217039633A patent/KR20220030933A/ko active Pending
- 2020-05-07 BR BR112021022303A patent/BR112021022303A2/pt unknown
- 2020-05-07 JP JP2021566150A patent/JP7723887B2/ja active Active
- 2020-05-07 CA CA3139011A patent/CA3139011A1/en active Pending
- 2020-05-07 WO PCT/US2020/031796 patent/WO2020227483A1/en not_active Ceased
- 2020-05-07 SG SG11202111973RA patent/SG11202111973RA/en unknown
- 2020-05-07 CN CN202510969431.7A patent/CN120939220A/zh active Pending
- 2020-05-07 EA EA202193074A patent/EA202193074A1/ru unknown
- 2020-05-07 AU AU2020267641A patent/AU2020267641B2/en active Active
- 2020-05-07 EP EP20802730.0A patent/EP3966235A4/en active Pending
- 2020-05-07 MX MX2021013588A patent/MX2021013588A/es unknown
- 2020-05-07 MA MA055911A patent/MA55911A/fr unknown
- 2020-05-07 CN CN202080044323.4A patent/CN114375301B/zh active Active
- 2020-05-07 US US17/608,860 patent/US12590136B2/en active Active
-
2021
- 2021-11-01 IL IL287777A patent/IL287777A/en unknown
- 2021-11-08 CL CL2021002935A patent/CL2021002935A1/es unknown
- 2021-12-02 CO CONC2021/0016480A patent/CO2021016480A2/es unknown
-
2025
- 2025-02-28 JP JP2025031484A patent/JP2025078698A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535275A5 (https=) | ||
| JPWO2020227483A5 (https=) | ||
| Sinkovics et al. | New developments in the virus therapy of cancer: a historical review | |
| AU2015230741B9 (en) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof | |
| CN107207613B (zh) | 含Toll样受体胞内结构域的嵌合抗原受体 | |
| Jewett et al. | Interferon-α activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-α secretion by immature human natural killer cells | |
| WO2020247392A1 (en) | Combinations of engineered natural killer cells and engineered t cells for immunotherapy | |
| RU2020122708A (ru) | Рецепторы nkg2d daric | |
| Simon et al. | Monoclonal antibodies to interferon-gamma inhibit interleukin 2-dependent induction of growth and maturation in lectin/antigen-reactive cytolytic T lymphocyte precursors. | |
| US20210379149A1 (en) | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | |
| JP2019532674A5 (https=) | ||
| US20240287456A1 (en) | A method for producing antigen-specific t cells | |
| US12590139B2 (en) | MHC class II molecules and methods of use thereof | |
| Oldham | Biotherapy: the fourth modality of cancer treatment | |
| TW202140534A (zh) | 個人化醫藥 | |
| Belldegrun et al. | Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid | |
| Van de Griend et al. | Rapid expansion of allospecific cytotoxic T cell clones using nonspecific feeder cell lines without further addition of exogenous IL2 | |
| CN114853880A (zh) | Wt1抗原特异性t细胞受体及其抗肿瘤用途 | |
| Volkman et al. | Human T cell leukemia/lymphoma virus-infected antigen-specific T cell clones: indiscriminant helper function and lymphokine production. | |
| Mingari et al. | Phenotypic and functional analysis of human CD3+ and CD3− clones with “lymphokine‐activated killer”(LAK) activity. Frequent occurrence of CD3+ LAK clones which produce interleukin‐2 | |
| US20230348561A1 (en) | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof | |
| Trentin et al. | Functional role of IL-2 receptors on tumour-infiltrating lymphocytes | |
| Ting et al. | Lymphokine-induced cytotoxicity: characterization of effectors, precursors, and regulatory ancillary cells | |
| JPWO2020227475A5 (https=) | ||
| Al-Khami et al. | Adoptive immunotherapy of cancer: Gene transfer of T cell specificity |